Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 1/25/19 → 12/6/20 |
Funding
- Vertex Pharmaceuticals Inc: $65,497.00
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older with Cystic Fibrosis
- Pancham, Krishna (PI)
- Anstead, Michael (CoI)